Tuberculosis Clinical Trial
Official title:
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers
NCT number | NCT02709278 |
Other study ID # | TB041 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | March 7, 2016 |
Est. completion date | May 9, 2019 |
Verified date | November 2023 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
TB041 is a clinical challenge trial primarily to evaluate the safety of BCG challenge administered by the aerosol inhaled route in healthy, BCG naive UK adults. The trial will also look to evaluate and compare the amount of BCG recovered from the lungs and from the skin, following challenge by either the aerosol or the intradermal route.
Status | Completed |
Enrollment | 46 |
Est. completion date | May 9, 2019 |
Est. primary completion date | May 9, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Healthy adult aged 18-50 years - Resident in or near Oxford (CCVTM or OUH) or Birmingham (NIHR-WTCRF) for the = duration of the trial period - Screening IGRA negative - Chest radiograph normal - No relevant findings in medical history or on physical examination - Allow the Investigators to discuss the individual's medical history with their GP - Use effective contraception (see below) for the duration of the trial period (females only) - Refrain from blood donation during the trial - Give written informed consent - Allow the Investigator to register volunteer details with a confidential database (The - Over-volunteering Protection Service) to prevent concurrent entry into clinical studies/trials - Able and willing (in the Investigator's opinion) to comply with all the trial requirements Exclusion Criteria: - Previously resident for more than 12 months concurrently in a tropical climate where significant non-tuberculous mycobacterial exposure is likely - Participation in another research trial involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period - Prior vaccination with BCG or any candidate TB vaccine - Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial challenge date - Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse - Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents - History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial agent, sedative drugs, or any local or general anaesthetic agents - Pregnancy, lactation or intention to become pregnant during trial period Any respiratory disease, including asthma - Current smoker - Clinically significant abnormality on screening chest radiograph - Clinically significant abnormality of spirometry - Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy - Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs - Clinical, radiological, or laboratory evidence of current active TB disease - Past treatment for TB disease - Any clinically significant abnormality of screening blood or urine tests - Positive HBsAg, HCV or HIV antibodies - Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NIHR Wellcome Trust Clinical Research Facility, University of Birmingham | Birmingham | West Midlands |
United Kingdom | Centre for Clinical Vaccinology and Tropical Medicine , University of Oxford | Oxford | Oxfordshire |
United Kingdom | Oxford University Hospitals- John Warin Ward, University of Oxford | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | University of Birmingham |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Identification of cellular markers of immunity | Established and exploratory markers of innate, cell mediated and humoral immunity in blood and BAL samples will be used to identify cellular markers of immunity to BCG. | Up to day 168 | |
Other | Evaluation of aerosol BCG challenge vs intradermal BCG challenge | Laboratory markers of cell mediated and humoral immunity, including ex-vivo ELISpot in blood and intracellular cytokine staining in blood and BAL samples will be used to assess which route of challenge is most effective | Up to day 168 | |
Primary | Adverse Events (AE) | Collection of AE data at each visit and via diary card for 28 days after challenge. | Up to day 168 | |
Secondary | Quantification of BCG | Quantification of BCG in bronchoalveolar lavage (BAL) sample and intradermal biopsy sample. | At day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |